June 20, 2017
The Federation of Pharmaceutical Manufacturers’ Associations of Japan’s (FPMAJ) committee on drug pricing affairs presented its views on cost-effective assessments (CEAs) in a report announced on June 16. The report points out that it is not recommendable to reflect the...read more